reports
illumin Reports First Quarter 2024 Financial Results
illumin Reports First Quarter 2024 Financial Results Total First Quarter Revenue of $25.0 millionillumin Self-Service Revenue up 282% YoY (All monetary figures are expressed in Canadian dollars unless otherwise stated) TORONTO, May 09, 2024 (GLOBE NEWSWIRE) -- illumin Holdings Inc. (TSX: ILLM) (“illumin” or “Company”), a journey advertising technology company that empowers marketers to make smarter decisions about communicating with online consumers, today announced its financial results for the first quarter ended March 31, 2024. First Quarter 2024 Highlights First quarter 2024 reven...
M.Dias Branco S.A. Ind Com De Alimentos: 2 directors
Two Directors at M.Dias Branco S.A. Ind Com De Alimentos bought 309,182 shares at between 34.302BRL and 36.112BRL. The significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the co...
China Cultural Tourism And Agriculture Group Ltd: 1 director
A director at China Cultural Tourism And Agriculture Group Ltd sold 50,552,000 shares at 0.118HKD and the significance rating of the trade was 67/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...
Form 8.3 - Apex Fundrock Limited : Re Tyman plc
Apex Fundrock Limited (MISL) Form 8.3 - Apex Fundrock Limited : Re Tyman plc 09-May-2024 / 12:45 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), s...
Virios Therapeutics Announces First Quarter 2024 Financial Results and...
Virios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate Update - Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call Today at 8:30 a.m. ET - ATLANTA, May 09, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: VIRI) (the “Company”), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases, including (“FM”) and (“LC”), today announced financial results for...
Form 8.3 - Apex Fundrock Limited : Re Tyman plc
Apex Fundrock Limited (MISL) Form 8.3 - Apex Fundrock Limited : Re Tyman plc 09-May-2024 / 12:41 GMT/BST FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Chelverton Asset Management (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), s...
GN Store Nord: 1 director
A director at GN Store Nord bought 7,000 shares at 201.500DKK and the significance rating of the trade was 69/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly...
Widodo Makmur Perkasa Tbk PT: 1 director
A director at Widodo Makmur Perkasa Tbk PT bought 375,000,000 shares at 15.000IDR and the significance rating of the trade was 56/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the la...
Arbona AB: 1 director
A director at Arbona AB sold 75,000 shares at 3.000SEK and the significance rating of the trade was 51/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearly showin...
Moody's Ratings affirms Daegu Bank's A2 ratings, changes outlook to ne...
Moody's Ratings (Moody's) has affirmed Daegu Bank, Ltd.'s A2 foreign-currency and local-currency long-term bank deposit ratings and changed their outlooks to negative from stable. At the same time, Moody's has affirmed Daegu Bank's baa1 Baseline Credit Assessment (BCA) and Adjusted BCA, the bank's...
Moody's Ratings affirms Daegu Bank's A2 ratings, changes outlook to ne...
MOODY'S INVESTORS SERVICE 1Moody's Ratings, 대구은행의 ‘A2’ 신용등급 재확인; 전망 ‘부정적’으로 조정 2024 년 5 월 9 일、 홍콩 、 한국어 보도자료는 영문 보도자료의 번역본입니다. 한국어와 영문 보도자료 간에 상이한 점이 있을 경우 영어 원문이 우선합니다.Moody’s Ratings(이하 ‘무디스’)는 대구은행의 ‘A2’ 외화표시 및 현지통화표시 장기 은행예금등급을 재확인하고, 전망을 종전의 ‘안정적’에서 ‘부정적’으로 조정하였다.동시에 무디스는 대구은행의 ‘baa1’ 독자신용도(BCA...
Swire Pacific Ltd: 1 director
A director at Swire Pacific Ltd sold 527,500 shares at 10.747HKD and the significance rating of the trade was 72/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clea...
GFL Environmental Inc: 1 director
A director at GFL Environmental Inc sold/sold after exercising options 86,820 shares at 44.920CAD and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's direc...
Kelly Reports First-Quarter 2024 Earnings
Kelly Reports First-Quarter 2024 Earnings Q1 operating earnings of $26.8 million, or up 34% on an adjusted basis Q1 revenue down following sale of European staffing operations; down 2.6% on an organic basis Q1 adjusted EBITDA margin increased 110 basis points to 3.2% driven by meaningful reduction in operating expenses resulting from business transformation initiatives and sale of European staffing operations Company expects further expansion of EBITDA margin from the planned Q2 2024 acquisition of Motion Recruitment Partners, LLC ("MRP") and ongoing transformation actions TROY, Mich., M...
Black Diamond Therapeutics Reports First Quarter 2024 Financial Result...
Black Diamond Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update Initial Phase 2 data of BDTX-1535 in 2L/3L EGFRm NSCLC patients on track for Q3 2024Enrollment ongoing in Phase 2 trial of BDTX-1535 in 1L patients with non-classical EGFRm NSCLC; initial data expected Q1 2025Presented real world evidence on the evolving EGFR mutation landscape in NSCLC, and the potential of BDTX-1535 across multiple lines of therapy at the 2024 AACR annual meetingPoster presentations upcoming June 1st at 2024 ASCO Annual Meeting on BDTX-1535 in GBM patients: Phase 1 dose-e...
Knight Therapeutics Enters into Exclusive Supply and Distribution Agre...
Knight Therapeutics Enters into Exclusive Supply and Distribution Agreement with Ironshore Pharmaceuticals & Development, Inc. for JORNAY PM® for Canada and Latin America MONTREAL, May 09, 2024 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. (TSX: GUD) ("Knight"), a pan-American (ex-USA) specialty pharmaceutical company, announced today that it has entered into an exclusive supply and distribution agreement with Ironshore Pharmaceuticals & Development, Inc., a wholly owned subsidiary of Ironshore Therapeutics, Inc. (“Ironshore”), granting Knight the rights to seek regulatory approval and com...
Thérapeutique Knight conclut une entente exclusive d’approvisionnement...
Thérapeutique Knight conclut une entente exclusive d’approvisionnement et de distribution avec Ironshore Pharmaceuticals & Development, Inc. pour JORNAY PM® pour le Canada et l’Amérique latine MONTRÉAL, 09 mai 2024 (GLOBE NEWSWIRE) -- Thérapeutique Knight Inc. (TSX : GUD) (« Knight »), société pharmaceutique spécialisée panaméricaine (hors États-Unis), a annoncé aujourd’hui la conclusion d’une entente exclusive d’approvisionnement et de distribution avec Ironshore Pharmaceuticals & Development, Inc., une filiale en propriété exclusive d’Ironshore Therapeutics, Inc. (« Ironshore »), octroy...
Century Therapeutics Reports First Quarter 2024 Financial Results and ...
Century Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Updates - Announced plans to pursue additional autoimmune disease regulatory filings for its iPSC derived NK cell therapy, CNTY-101, beyond systemic lupus erythematosus (SLE) - Closed $60 million private placement led by Bain Capital Life Sciences supporting accelerated expansion in autoimmune disease - Acquired Clade Therapeutics bringing enhancement of Allo-Evasion™ platform and three preclinical stage αβ iT programs spanning across cancer and autoimmune diseases - Additional clinical data from Pha...
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare...
Pyxis Oncology to Present at the RBC Capital Markets Global Healthcare Conference BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical stage company focused on developing next generation therapeutics to target difficult-to-treat cancers, announced today that Lara S. Sullivan, M.D., President and Chief Executive Officer, will participate in a fireside chat on Tuesday, May 14, 2024 at 3:05 PM ET at the RBC Capital Markets Global Healthcare Conference, where members of management will also host investor one-on-one meetings. A live webcast and replay of th...
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Ter...
Coherus Announces Full Repayment of Pharmakon Advisors $75 Million Term Loan – New $38.7 million term loan with a May 2029 maturity –– $37.5 million royalty monetization financing based on future sales of LOQTORZI® and UDENYCA® – REDWOOD CITY, Calif., May 09, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (Coherus, Nasdaq: CHRS), today announced it entered into a combined term loan and product royalty financing agreement with Barings that has allowed Coherus to fully pay off the remaining $75 million of its Pharmakon Advisors term loan. This further reduces the Company’s term loan...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.